Artículos

Qtc variability in schizophrenia patients treated with antipsychotics and healthy controls / Maria A. Rettenbacher en Journal of Clinical Psychopharmacology, Año 2005 - Vol. 25 - No. 3 (Junio)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 3 (Junio) . - pp. 206-210 Título : Qtc variability in schizophrenia patients treated with antipsychotics and healthy controls Tipo de documento: texto impreso Autores: Maria A. Rettenbacher, Autor ; Ursula Eder Ischia, Autor ; Angelika Bader, Autor Fecha de publicación: 2023 Artículo en la página: pp. 206-210 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Electrocardiografía, Síndrome de QT largo, Esquizofrenia. Resumen: QTc prolongation is associated with the administration of some antipsychotics but the QTc interval is also known to vary physiologically. There is little published evidence about changes in QTc variability during treatment with antipsychotics. In this prospective investigation, we analyzed ECGs in 61 patients suffering from a schizophrenic disorder who were treated with different antipsychotics and 31 sex- and age-matched healthy controls. Link: ./index.php?lvl=notice_display&id=30903 [artículo] Qtc variability in schizophrenia patients treated with antipsychotics and healthy controls [texto impreso] / Maria A. Rettenbacher, Autor ; Ursula Eder Ischia, Autor ; Angelika Bader, Autor . - 2023 . - pp. 206-210. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 3 (Junio) . - pp. 206-210 Palabras clave: Antipsicóticos, Electrocardiografía, Síndrome de QT largo, Esquizofrenia. Resumen: QTc prolongation is associated with the administration of some antipsychotics but the QTc interval is also known to vary physiologically. There is little published evidence about changes in QTc variability during treatment with antipsychotics. In this prospective investigation, we analyzed ECGs in 61 patients suffering from a schizophrenic disorder who were treated with different antipsychotics and 31 sex- and age-matched healthy controls. Link: ./index.php?lvl=notice_display&id=30903

Influence of topiramate on olanzapine-related adiposity in women / Marius K. Nickel en Journal of Clinical Psychopharmacology, Año 2005 - Vol. 25 - No. 3 (Junio)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 3 (Junio) . - pp. 211-217 Título : Influence of topiramate on olanzapine-related adiposity in women : A random, double-blind, placebo-controlled study Tipo de documento: texto impreso Autores: Marius K. Nickel, Autor ; Cerstin Nickel, Autor ; Moritz Muehlbacher, Autor Fecha de publicación: 2023 Artículo en la página: pp. 211-217 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Tejido adiposo, Agentes contra la obesidad, Benzodiacepinas, Fructosa, Trastornos mentales, Pruebas Neuropsicológicas, Aumento de peso, Pérdida de peso. Resumen: The aim of this study was to compare the efficacy of topiramate versus a placebo in the treatment of adiposity in women undergoing olanzapine therapy. We also assessed changes health-related quality of life, the patient's actual state of health, and psychologic impairments. Link: ./index.php?lvl=notice_display&id=30904 [artículo] Influence of topiramate on olanzapine-related adiposity in women : A random, double-blind, placebo-controlled study [texto impreso] / Marius K. Nickel, Autor ; Cerstin Nickel, Autor ; Moritz Muehlbacher, Autor . - 2023 . - pp. 211-217. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 3 (Junio) . - pp. 211-217 Palabras clave: Tejido adiposo, Agentes contra la obesidad, Benzodiacepinas, Fructosa, Trastornos mentales, Pruebas Neuropsicológicas, Aumento de peso, Pérdida de peso. Resumen: The aim of this study was to compare the efficacy of topiramate versus a placebo in the treatment of adiposity in women undergoing olanzapine therapy. We also assessed changes health-related quality of life, the patient's actual state of health, and psychologic impairments. Link: ./index.php?lvl=notice_display&id=30904

A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia / A. Eden Evins en Journal of Clinical Psychopharmacology, Año 2005 - Vol. 25 - No. 3 (Junio)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 3 (Junio) . - pp. 218-225 Título : A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia Tipo de documento: texto impreso Autores: A. Eden Evins, Autor ; Corinne Cather, Autor ; Thilo Deckersbach, Autor Fecha de publicación: 2023 Artículo en la página: pp. 218-225 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Bupropión, Esquizofrenia, Tabaquismo, Fumar - metabolismo, Tabaquismo - psicología Resumen: The objective of this study was to examine the efficacy of bupropion for smoking cessation in patients with schizophrenia. Adults with schizophrenia who smoked more than 10 cigarettes per day and wished to try to quit smoking were recruited from community mental health centers, enrolled in a 12-week group cognitive behavioral therapy intervention, and randomly assigned to receive either bupropion sustained-release 300 mg/d or identical placebo. Link: ./index.php?lvl=notice_display&id=30905 [artículo] A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia [texto impreso] / A. Eden Evins, Autor ; Corinne Cather, Autor ; Thilo Deckersbach, Autor . - 2023 . - pp. 218-225. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 3 (Junio) . - pp. 218-225 Palabras clave: Bupropión, Esquizofrenia, Tabaquismo, Fumar - metabolismo, Tabaquismo - psicología Resumen: The objective of this study was to examine the efficacy of bupropion for smoking cessation in patients with schizophrenia. Adults with schizophrenia who smoked more than 10 cigarettes per day and wished to try to quit smoking were recruited from community mental health centers, enrolled in a 12-week group cognitive behavioral therapy intervention, and randomly assigned to receive either bupropion sustained-release 300 mg/d or identical placebo. Link: ./index.php?lvl=notice_display&id=30905

Inhibition of cyp2d6 activity by bupropion / Michael Kotlyar en Journal of Clinical Psychopharmacology, Año 2005 - Vol. 25 - No. 3 (Junio)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 3 (Junio) . - pp. 226-229 Título : Inhibition of cyp2d6 activity by bupropion Tipo de documento: texto impreso Autores: Michael Kotlyar, Autor ; Lisa H. Brauer, Autor ; Timothy S. Tracy, Autor Fecha de publicación: 2023 Artículo en la página: pp. 226-229 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Bupropión, Citocromo P-450 CYP2D6, Inhibidores del citocromo P-450 CYP2D6, Dextrometorfano, Inhibidores de enzimas. Resumen: The purpose of this study was to assess the effect of bupropion on cytochrome P450 2D6 (CYP2D6) activity. Twenty-one subjects completed this repeated-measures study in which dextromethorphan (30-mg oral dose) was administered to smokers at baseline and after 17 days of treatment with either bupropion sustained-release (150 mg twice daily) or matching placebo. Link: ./index.php?lvl=notice_display&id=30906 [artículo] Inhibition of cyp2d6 activity by bupropion [texto impreso] / Michael Kotlyar, Autor ; Lisa H. Brauer, Autor ; Timothy S. Tracy, Autor . - 2023 . - pp. 226-229. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 3 (Junio) . - pp. 226-229 Palabras clave: Bupropión, Citocromo P-450 CYP2D6, Inhibidores del citocromo P-450 CYP2D6, Dextrometorfano, Inhibidores de enzimas. Resumen: The purpose of this study was to assess the effect of bupropion on cytochrome P450 2D6 (CYP2D6) activity. Twenty-one subjects completed this repeated-measures study in which dextromethorphan (30-mg oral dose) was administered to smokers at baseline and after 17 days of treatment with either bupropion sustained-release (150 mg twice daily) or matching placebo. Link: ./index.php?lvl=notice_display&id=30906

Efficacy of buspirone in the treatment of opioid withdrawal / Laure Buydens Branchey en Journal of Clinical Psychopharmacology, Año 2005 - Vol. 25 - No. 3 (Junio)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 3 (Junio) . - pp. 230-236 Título : Efficacy of buspirone in the treatment of opioid withdrawal Tipo de documento: texto impreso Autores: Laure Buydens Branchey, Autor ; Marc Branchey, Autor ; Christine Reel Brander, Autor Fecha de publicación: 2023 Artículo en la página: pp. 230-236 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Buspirona, Trastornos relacionados con opioides, Síndrome de abstinencia de sustancias. Resumen: In an attempt to develop a new opiate detoxification approach, the authors assessed the efficacy of buspirone in the treatment of acute heroin withdrawal. Buspirone, a drug interacting with the serotonergic system, was selected because there is evidence that a decrease in serotonergic neurotransmission may be involved in opiate withdrawal symptoms. Link: ./index.php?lvl=notice_display&id=30907 [artículo] Efficacy of buspirone in the treatment of opioid withdrawal [texto impreso] / Laure Buydens Branchey, Autor ; Marc Branchey, Autor ; Christine Reel Brander, Autor . - 2023 . - pp. 230-236. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 3 (Junio) . - pp. 230-236 Palabras clave: Buspirona, Trastornos relacionados con opioides, Síndrome de abstinencia de sustancias. Resumen: In an attempt to develop a new opiate detoxification approach, the authors assessed the efficacy of buspirone in the treatment of acute heroin withdrawal. Buspirone, a drug interacting with the serotonergic system, was selected because there is evidence that a decrease in serotonergic neurotransmission may be involved in opiate withdrawal symptoms. Link: ./index.php?lvl=notice_display&id=30907

The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia / Joseph I. Friedman en Journal of Clinical Psychopharmacology, Año 2005 - Vol. 25 - No. 3 (Junio)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 3 (Junio) . - pp. 237-242 Título : The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia Tipo de documento: texto impreso Autores: Joseph I. Friedman, Autor ; Ramoncito Ocampo, Autor ; Zeinab Elbaz, Autor Fecha de publicación: 2023 Artículo en la página: pp. 237-242 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Citalopram, Cognición, Terapia con medicamentos, Pruebas Neuropsicológicas, Esquizofrenia, Psicología esquizofrénica. Resumen: Cognitive enhancement in patients with schizophrenia is a major treatment priority. Because serotonergic approaches have been suggested as a possible mechanism to enhance cognition and many patients with schizophrenia are treated with selective serotonin reuptake inhibitor antidepressants, we evaluated a serotonin reuptake inhibitor, citalopram, as adjunctive therapy to atypical antipsychotic treatment for its cognitive enhancing effects in schizophrenic patients. Link: ./index.php?lvl=notice_display&id=30908 [artículo] The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia [texto impreso] / Joseph I. Friedman, Autor ; Ramoncito Ocampo, Autor ; Zeinab Elbaz, Autor . - 2023 . - pp. 237-242. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 3 (Junio) . - pp. 237-242 Palabras clave: Antipsicóticos, Citalopram, Cognición, Terapia con medicamentos, Pruebas Neuropsicológicas, Esquizofrenia, Psicología esquizofrénica. Resumen: Cognitive enhancement in patients with schizophrenia is a major treatment priority. Because serotonergic approaches have been suggested as a possible mechanism to enhance cognition and many patients with schizophrenia are treated with selective serotonin reuptake inhibitor antidepressants, we evaluated a serotonin reuptake inhibitor, citalopram, as adjunctive therapy to atypical antipsychotic treatment for its cognitive enhancing effects in schizophrenic patients. Link: ./index.php?lvl=notice_display&id=30908

Hyperforin plasma level as a marker of treatment adherence in the national institutes of health hypericum depression trial / Benedetto Vitiello en Journal of Clinical Psychopharmacology, Año 2005 - Vol. 25 - No. 3 (Junio)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 3 (Junio) . - pp. 243-249 Título : Hyperforin plasma level as a marker of treatment adherence in the national institutes of health hypericum depression trial Tipo de documento: texto impreso Autores: Benedetto Vitiello, Autor ; Richard I. Shader, Autor ; Corette B. Parker, Autor Fecha de publicación: 2023 Artículo en la página: pp. 243-249 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno depresivo mayor, Institutos Nacionales de Salud (EE. UU.), Floroglucinol, Terpenos. Resumen: A previously reported clinical trial of Hypericum perforatum (St John's wort) in depression did not demonstrate efficacy. We assessed treatment adherence by measuring plasma hyperforin and evaluated the possible impact of adherence on study results. Link: ./index.php?lvl=notice_display&id=30909 [artículo] Hyperforin plasma level as a marker of treatment adherence in the national institutes of health hypericum depression trial [texto impreso] / Benedetto Vitiello, Autor ; Richard I. Shader, Autor ; Corette B. Parker, Autor . - 2023 . - pp. 243-249. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2005 - Vol. 25 - No. 3 (Junio) . - pp. 243-249 Palabras clave: Trastorno depresivo mayor, Institutos Nacionales de Salud (EE. UU.), Floroglucinol, Terpenos. Resumen: A previously reported clinical trial of Hypericum perforatum (St John's wort) in depression did not demonstrate efficacy. We assessed treatment adherence by measuring plasma hyperforin and evaluated the possible impact of adherence on study results. Link: ./index.php?lvl=notice_display&id=30909